NEW YORK (GenomeWeb) — NeoGenomics announced today that it has signed a group purchasing agreement for its clinical reference laboratory testing services with healthcare provider network Premier.
Under the terms of the deal, Premier members — which include roughly 4,000 hospitals and 165,000 other providers throughout the US — can access NeoGenomics services at special pre-negotiated prices and terms. Additional terms were not disclosed.
Included in the arrangement are NeoGenomics' bone marrow and surgical pathology consults; cancer cytogenetics; hematologic and solid tumor FISH testing; and more than 150 molecular oncology tests.
"The agreement underscores NeoGenomics' unique position as a national, oncology-focused laboratory," NeoGenomics Chairman and CEO Douglas VanOort said in a statement. "We look forward to providing a comprehensive suite of cancer tests, along with our tradition of outstanding customer service, to Premier members across the country."
NeoGenomics — which recently reported a 9 percent increase in Q2 revenues amid improved performance of its clinical services division — signed a similar purchasing agreement with Premier in 2015.